Gamma-1 MSH: natural brain peptide linked to appetite and sexual function
A small hormone the body makes naturally in the brain and pituitary gland; it helps regulate appetite, energy balance, and sexual function; experimental, not yet an approved drug.
- Class
- Endogenous pituitary peptide fragment
- Status
- No approved therapeutic status identified
- Main caveat
- Source file is a catalog entry with sequence and two 1979 structural-characterization citations; no bioactivity, mechanism, safety, or clinical data are present in the compiled source.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
γ1-MSH (gamma-1 melanocyte-stimulating hormone) is a small 11-amino-acid peptide that the body produces naturally from a large precursor protein called POMC (pro-opiomelanocortin). POMC is processed in the brain and pituitary gland into at least eight distinct signaling molecules — including ACTH, β-endorphin, and the three γ-MSH variants — and γ1-MSH is the shortest of those γ-MSH products (Ericson and colleagues, BBA Molecular Basis of Disease, 2017). The stored sequence YVMGHFRWDRF represents the core 11 residues; the native processed form documented in the literature carries an additional N-terminal lysine and a C-terminal amide (-NH₂), neither of which is captured in the stored sequence. γ1-MSH acts mainly at the melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R), both of which are expressed in brain regions governing energy balance.
History
The γ-MSH peptides were identified as part of the systematic characterization of POMC processing products during the 1980s and 1990s. The POMC N-terminal domain was recognized as the source of three related γ-MSH forms — γ1-MSH (11 residues), γ2-MSH (12 residues, the N-terminal portion of γ3-MSH), and γ3-MSH (23 residues, N-glycosylated) — each produced by differential proteolytic cleavage (Ericson and colleagues, 2017). The discovery emerged from the broader effort to map how a single prohormone gene gives rise to multiple functionally distinct peptides depending on cell type and processing enzymes. Interest in the γ-MSH family accelerated alongside the cloning of the five melanocortin receptor subtypes (MC1R–MC5R) in the early 1990s, which provided a framework for understanding why structurally related POMC fragments could have distinct physiological roles (Dores, Frontiers in Neuroscience, 2013).
What it does
γ1-MSH binds to melanocortin receptors in the brain, particularly MC3R and MC4R, which sit at the center of the neural circuitry controlling energy intake and expenditure. The MC4R pathway is one of the most studied systems in obesity biology: activation of MC4R reduces food intake and increases energy expenditure, while loss-of-function MC4R mutations are the most common single-gene cause of severe early-onset obesity in humans (Yeo and colleagues, Molecular Metabolism, 2021). γ1-MSH shares the core HFRW pharmacophore that is also present in α-MSH and β-MSH, which is the structural motif responsible for melanocortin receptor engagement across the family (Ericson and colleagues, 2017).
Despite this receptor profile, the effects of γ1-MSH on food intake are not straightforward. Intracerebroventricular administration of γ1-MSH did not suppress food intake in rats following a 48-hour fast, whereas γ2-MSH administered by the same route produced a significant but delayed inhibition of food intake in similarly fasted animals (Ericson and colleagues, 2017). This divergence between closely related POMC fragments illustrates that receptor binding profile alone does not predict functional outcome — potency, selectivity ratios between MC3R and MC4R, and local neuroanatomical context all matter.
Evidence
- Human: No human clinical trials for γ1-MSH itself have been published or registered. The broader MC4R pathway has been validated in humans through clinical work on synthetic agonists: RM-493 (setmelanotide) increased resting energy expenditure in obese individuals in a randomized, double-blind, placebo-controlled crossover study (Chen and colleagues, Journal of Clinical Endocrinology & Metabolism, 2015), and setmelanotide has since been approved for severe obesity caused by rare genetic defects in POMC pathway signaling (Qamar and colleagues, touchREVIEWS in Endocrinology, 2024).
- Animal: Intracerebroventricular γ1-MSH did not suppress food intake in fasted rats; γ2-MSH produced delayed inhibition under the same conditions (Ericson and colleagues, 2017). These findings suggest that γ1-MSH has weaker or more context-dependent effects on energy balance compared with other γ-MSH variants.
- In vitro: Structure–activity relationship studies on MC3R/MC4R/MC5R-selective analogs derived from the γ-MSH and α-MSH scaffold have characterized the contributions of individual residues to receptor potency and selectivity (Grieco and colleagues, Journal of Peptide Research, 2003), providing the mechanistic basis for drug design around this receptor family.
Known effects
- MC3R agonism — Preclinical; γ1-MSH binds MC3R; the functional consequences of selective MC3R activation in energy balance are an ongoing area of research
- MC4R agonism — Preclinical; γ1-MSH engages MC4R; full MC4R agonism drives reduced food intake and increased energy expenditure in animal models, but this effect was not demonstrated for γ1-MSH in the intracerebroventricular rat model
- POMC-pathway modulation — Mechanistic; as an endogenous POMC product, γ1-MSH is part of the physiological melanocortin signaling network governing energy homeostasis
Regulatory status
- US: γ1-MSH is an unapproved research peptide. No IND or NDA on record. Not FDA-approved for any indication.
- EU: Not approved by the EMA.
- Research use: Used as a reference ligand and structural template in melanocortin receptor pharmacology research.
Mechanism
γ1-MSH is a partial-sequence POMC fragment sharing the core His-Phe-Arg-Trp (HFRW) tetrapeptide motif that is the primary receptor-binding pharmacophore across all endogenous melanocortin peptides (Ericson and colleagues, 2017). This motif engages the orthosteric binding site of MC3R and MC4R, which are Gs-coupled receptors. Activation of these receptors elevates intracellular cAMP, triggering downstream signaling cascades involved in appetite regulation, energy expenditure, and autonomic tone (Yeo and colleagues, 2021). MC4R in particular is expressed in hypothalamic nuclei (paraventricular nucleus, arcuate nucleus) that integrate leptin and insulin signals to set long-term energy balance (Yoon and colleagues, Endocrinology and Metabolism, 2015). The melanocortin receptor system as a whole — including MC1R through MC5R — has been extensively pursued as a therapeutic target for obesity, inflammatory disease, and sexual dysfunction (Cai and colleagues, Current Protein & Peptide Science, 2016; Ericson and colleagues, 2017). Despite decades of drug discovery effort targeting MC4R specifically for general obesity, many synthetic agonists failed in clinical development due to problems with potency, selectivity, or cardiovascular side effects, with setmelanotide succeeding only in rare monogenic obesity subgroups where MC4R pathway activity is deficient (Prindle and colleagues, Frontiers in Endocrinology, 2026).
Open questions
- Whether γ1-MSH has distinct physiological roles beyond energy balance (e.g., cardiovascular regulation, inflammatory modulation via MC3R) has not been systematically characterized
- The basis for the functional divergence between γ1-MSH and γ2-MSH in food intake suppression — whether it reflects differential MC3R vs. MC4R engagement, differences in receptor selectivity, or pharmacokinetic differences in the CNS — remains unresolved
- No proteolytic stability or pharmacokinetic data for γ1-MSH in vivo appear in the literature
- The physiological significance of the C-terminal amide on native γ-MSH in receptor binding and in vivo activity compared with the non-amidated form has not been fully characterized for this specific fragment
Related peptides
- α-MSH — the best-characterized endogenous MC1R/MC4R agonist, sharing the HFRW core; N-terminally acetylated and C-terminally amidated 13-mer also derived from POMC
- Setmelanotide — a synthetic cyclic MC4R-selective agonist approved for rare genetic obesity; illustrates what targeted MC4R pharmacology can achieve clinically
- PT-141 (bremelanotide) — synthetic melanocortin agonist acting at MC3R/MC4R, approved for hypoactive sexual desire disorder; descended from α-MSH analogs developed on the same HFRW scaffold
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
If the methionine in γ1-MSH were replaced with a similar but more stable building block, would the resulting peptide keep its receptor activity while resisting breakdown?
A stable version of γ1-MSH could be manufactured reliably and stored without degradation, removing a key practical obstacle to turning this natural brain peptide into a medicine.
Does the amide group on the natural form of γ1-MSH specifically tune it to activate MC3R rather than the MC4R obesity receptor?
If confirmed, adding or removing this cap could let researchers dial in receptor preference, enabling more targeted drugs for energy balance or inflammation with fewer off-target effects.
Could γ1-MSH quiet inflammation through MC3R in immune cells without also triggering the appetite-related effects that make MC3R drugs hard to use?
Separating the inflammatory and metabolic effects of MC3R could open a path to anti-inflammatory medicines that do not disrupt eating behavior, which is a major unmet need in autoimmune disease treatment.
Do the three ring-shaped amino acids in γ1-MSH cluster together in solution to pre-form the receptor-ready shape?
If this self-organization is real, it explains why such a short natural peptide binds so well, and gives drug designers a blueprint for engineering compact, potent receptor-targeting molecules.
Is this 11-amino-acid fragment the shortest natural piece of the melanocortin system that can still switch on the MC3R receptor?
Knowing the shortest active form helps chemists design smaller, cheaper, and potentially more drug-like molecules for treating obesity or inflammatory conditions linked to MC3R.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8950616121292114 | boltz-2 |
| ranking score | 0.8176180720329285 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.613 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10720,
sequence = {YVMGHFRWDRF},
target = {mc3r},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}